| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 245,500 | 267,300 | ||
| Restricted cash | 3,700 | 3,700 | ||
| Accounts receivable, net | 149,500 | 79,800 | ||
| Inventories, net | 356,300 | 338,600 | ||
| Prepaid expenses and other current assets | 25,600 | 24,000 | ||
| Assets held for sale | 6,300 | 6,100 | ||
| Total current assets | 786,900 | 719,500 | ||
| Property, plant and equipment, net | 209,800 | 216,100 | ||
| Intangible assets, net | 452,700 | 469,000 | ||
| Other assets | 11,600 | 12,500 | ||
| Total assets | 1,461,000 | 1,417,100 | ||
| Accounts payable | 57,400 | 63,700 | ||
| Accrued expenses | 13,900 | 13,600 | ||
| Accrued compensation | 36,600 | 31,500 | ||
| Other current liabilities | 24,100 | 13,600 | ||
| Liabilities held for sale | 4,500 | 4,700 | ||
| Total current liabilities | 136,500 | 127,100 | ||
| Debt | 663,100 | 667,800 | ||
| Deferred tax liability | 36,300 | 46,500 | ||
| Other liabilities | 42,600 | 39,500 | ||
| Total liabilities | 878,500 | 880,900 | ||
| Common stock, 0.001 par value per share 200.0 shares authorized, 60.6 and 59.9 shares issued 52.7 and 54.3 shares outstanding, respectively | 100 | 100 | ||
| Treasury stock, at cost, 7.9 and 5.6 common shares, respectively | 243,500 | 234,600 | ||
| Additional paid-in capital | 938,600 | 935,200 | ||
| Accumulated other comprehensive loss, net | -7,500 | -8,100 | ||
| Accumulated deficit | -105,200 | -156,400 | ||
| Total stockholders equity | 582,500 | 536,200 | ||
| Total liabilities and stockholders equity | 1,461,000 | 1,417,100 | ||
Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. (EBS)